Please enable JavaScript to continue using this application.

Compare $ANAB vs $DMRA | Chartloom

Compare

$ANAB vs $DMRA

AnaptysBio Inc · Damora Therapeutics Inc

ANAB

AnaptysBio Inc

DMRA

Damora Therapeutics Inc

Compare $ANAB vs $DMRA

Comparing AnaptysBio Inc and Damora Therapeutics Inc

ANABAnaptysBio Inc

DMRADamora Therapeutics Inc

ANABAnaptysBio Inc

Market cap

$1.36B

P/E (TTM)

14.99x

Forward P/E (NTM)

16.38x

Forward P/S (NTM)

10.95x

Rev growth (TTM)

92.9%

YTD performance

2.2%

52W performance

44.4%

FCF yield

1.3%

DMRADamora Therapeutics Inc

Market cap

$1.30B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-17.4%

52W performance

-17.4%

FCF yield

-3.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ANAB

DMRA

Detailed metrics comparison

ANAB

AnaptysBio Inc

DMRA

Damora Therapeutics Inc

Market Cap

ANAB$1.36B

DMRA$1.30B

Enterprise Value

ANAB$1.48B

DMRA$757M

Price

ANAB$45.95

DMRA$21.08

P/E Ratio

ANAB14.99x

DMRAN/A

P/S Ratio

ANAB5.73x

DMRA0.00x

EV/Sales

ANAB6.24x

DMRA0.00x

EV/EBITDA

ANAB10.83x

DMRA0.00x

P/B Ratio

ANAB137.06x

DMRA2.47x

P/FCF Ratio

ANAB75.37x

DMRAN/A

EV/FCF

ANAB82.17x

DMRA-17.00x

PEG Ratio

ANABN/A

DMRAN/A

Forward P/E (NTM)

ANAB16.38x

DMRAN/A

Forward P/S (NTM)

ANAB10.95x

DMRAN/A

Revenue (TTM)

ANAB$238M

DMRA$0

Revenue Growth (YoY)

ANAB92.9%

DMRAN/A

Forward Rev Growth

ANAB34.7%

DMRA346.9%

Gross Margin (TTM)

ANAB0.0%

DMRA0.0%

Operating Margin (TTM)

ANAB56.4%

DMRA0.0%

EBITDA Margin (TTM)

ANAB56.5%

DMRA0.0%

Net Margin (TTM)

ANAB82.4%

DMRA0.0%

FCF Margin (TTM)

ANAB7.6%

DMRAN/A

Net Income (TTM)

ANAB$196M

DMRA$-265M

FCF (TTM)

ANAB$18M

DMRA$-45M

EPS (TTM)

ANAB$3.07

DMRA-$4.34

ROE (TTM)

ANAB895.0%

DMRA-8306.0%

ROA (TTM)

ANAB57.4%

DMRA-7849.0%

ROIC (TTM)

ANAB63.2%

DMRA-8306.0%

Cash

ANAB$134M

DMRA$541M

Debt

ANAB$256M

DMRA$0

Net Cash/Debt

ANAB$-123M

DMRA$541M

Current Ratio (TTM)

ANAB5.61x

DMRA19.73x

Quick Ratio (TTM)

ANAB5.54x

DMRA19.70x

Debt/Equity (TTM)

ANAB24.23x

DMRA0.00x

Debt/Assets (TTM)

ANAB0.0%

DMRA0.0%

Interest Coverage (TTM)

ANABN/A

DMRAN/A

Net Debt/EBITDA (TTM)

ANAB0.00x

DMRA0.00x

Beta

ANAB0.82

DMRA-4.05

52W Performance

ANAB44.4%

DMRA-17.4%

YTD Performance

ANAB2.2%

DMRA-17.4%

% from 52W High

ANAB-37.3%

DMRA-39.6%

% from 52W Low

ANAB51.8%

DMRA27.8%

Asset Turnover (TTM)

ANAB0.70x

DMRA0.00x

FCF Yield (TTM)

ANAB1.3%

DMRA-3.4%

Earnings Yield (TTM)

ANAB14.4%

DMRA-20.4%

Dividend Yield (TTM)

ANABN/A

DMRAN/A

Rule of 40

ANAB100.5

DMRA0.0

EV/GP/RG

ANABN/A

DMRAN/A

Ticker research

View ANAB research View DMRA research

Metric	ANAB AnaptysBio Inc	DMRA Damora Therapeutics Inc
Market & Valuation
Market Cap	$1.36B	$1.30B
Enterprise Value	$1.48B	$757M
Price	$45.95	$21.08
P/E Ratio	14.99x	N/A
P/S Ratio	5.73x	0.00x
EV/Sales	6.24x	0.00x
EV/EBITDA	10.83x	0.00x
P/B Ratio	137.06x	2.47x
P/FCF Ratio	75.37x	N/A
EV/FCF	82.17x	-17.00x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	16.38x	N/A
Forward P/S (NTM)	10.95x	N/A
Revenue & Growth
Revenue (TTM)	$238M	$0
Revenue Growth (YoY)	92.9%	N/A
Forward Rev Growth	34.7%	346.9%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	56.4%	0.0%
EBITDA Margin (TTM)	56.5%	0.0%
Net Margin (TTM)	82.4%	0.0%
FCF Margin (TTM)	7.6%	N/A
Net Income (TTM)	$196M	$-265M
FCF (TTM)	$18M	$-45M
EPS (TTM)	$3.07	-$4.34
ROE (TTM)	895.0%	-8306.0%
ROA (TTM)	57.4%	-7849.0%
ROIC (TTM)	63.2%	-8306.0%
Financial Health
Cash	$134M	$541M
Debt	$256M	$0
Net Cash/Debt	$-123M	$541M
Current Ratio (TTM)	5.61x	19.73x
Quick Ratio (TTM)	5.54x	19.70x
Debt/Equity (TTM)	24.23x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.82	-4.05
52W Performance	44.4%	-17.4%
YTD Performance	2.2%	-17.4%
% from 52W High	-37.3%	-39.6%
% from 52W Low	51.8%	27.8%
Efficiency & Yields
Asset Turnover (TTM)	0.70x	0.00x
FCF Yield (TTM)	1.3%	-3.4%
Earnings Yield (TTM)	14.4%	-20.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	100.5	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ANAB research	View DMRA research

Valuation

P/E Ratio

ANAB

14.99x

P/S Ratio

DMRA

0.00x

ANAB

5.73x

EV/FCF

DMRA

-17.00x

ANAB

82.17x

Growth & revenue

Revenue Growth TTM

ANAB

92.9%

Forward Revenue Growth

DMRA

346.9%

ANAB

34.7%

Profitability & performance

Gross Margin

ANAB

0.0%

DMRA

0.0%

ROE

ANAB

895.0%

DMRA

-8306.0%

FCF Yield %

ANAB

1.3%

DMRA

-3.4%

52-Week Performance

ANAB

44.4%

DMRA

-17.4%

Detailed metrics comparison

ANAB

AnaptysBio Inc

DMRA

Damora Therapeutics Inc

Market Cap

ANAB$1.36B

DMRA$1.30B

Enterprise Value

ANAB$1.48B

DMRA$757M

Price

ANAB$45.95

DMRA$21.08

P/E Ratio

ANAB14.99x

DMRAN/A

P/S Ratio

ANAB5.73x

DMRA0.00x

EV/Sales

ANAB6.24x

DMRA0.00x

EV/EBITDA

ANAB10.83x

DMRA0.00x

P/B Ratio

ANAB137.06x

DMRA2.47x

P/FCF Ratio

ANAB75.37x

DMRAN/A

EV/FCF

ANAB82.17x

DMRA-17.00x

PEG Ratio

ANABN/A

DMRAN/A

Forward P/E (NTM)

ANAB16.38x

DMRAN/A

Forward P/S (NTM)

ANAB10.95x

DMRAN/A

Revenue (TTM)

ANAB$238M

DMRA$0

Revenue Growth (YoY)

ANAB92.9%

DMRAN/A

Forward Rev Growth

ANAB34.7%

DMRA346.9%

Gross Margin (TTM)

ANAB0.0%

DMRA0.0%

Operating Margin (TTM)

ANAB56.4%

DMRA0.0%

EBITDA Margin (TTM)

ANAB56.5%

DMRA0.0%

Net Margin (TTM)

ANAB82.4%

DMRA0.0%

FCF Margin (TTM)

ANAB7.6%

DMRAN/A

Net Income (TTM)

ANAB$196M

DMRA$-265M

FCF (TTM)

ANAB$18M

DMRA$-45M

EPS (TTM)

ANAB$3.07

DMRA-$4.34

ROE (TTM)

ANAB895.0%

DMRA-8306.0%

ROA (TTM)

ANAB57.4%

DMRA-7849.0%

ROIC (TTM)

ANAB63.2%

DMRA-8306.0%

Cash

ANAB$134M

DMRA$541M

Debt

ANAB$256M

DMRA$0

Net Cash/Debt

ANAB$-123M

DMRA$541M

Current Ratio (TTM)

ANAB5.61x

DMRA19.73x

Quick Ratio (TTM)

ANAB5.54x

DMRA19.70x

Debt/Equity (TTM)

ANAB24.23x

DMRA0.00x

Debt/Assets (TTM)

ANAB0.0%

DMRA0.0%

Interest Coverage (TTM)

ANABN/A

DMRAN/A

Net Debt/EBITDA (TTM)

ANAB0.00x

DMRA0.00x

Beta

ANAB0.82

DMRA-4.05

52W Performance

ANAB44.4%

DMRA-17.4%

YTD Performance

ANAB2.2%

DMRA-17.4%

% from 52W High

ANAB-37.3%

DMRA-39.6%

% from 52W Low

ANAB51.8%

DMRA27.8%

Asset Turnover (TTM)

ANAB0.70x

DMRA0.00x

FCF Yield (TTM)

ANAB1.3%

DMRA-3.4%

Earnings Yield (TTM)

ANAB14.4%

DMRA-20.4%

Dividend Yield (TTM)

ANABN/A

DMRAN/A

Rule of 40

ANAB100.5

DMRA0.0

EV/GP/RG

ANABN/A

DMRAN/A

Ticker research

View ANAB research View DMRA research

Metric	ANAB AnaptysBio Inc	DMRA Damora Therapeutics Inc
Market & Valuation
Market Cap	$1.36B	$1.30B
Enterprise Value	$1.48B	$757M
Price	$45.95	$21.08
P/E Ratio	14.99x	N/A
P/S Ratio	5.73x	0.00x
EV/Sales	6.24x	0.00x
EV/EBITDA	10.83x	0.00x
P/B Ratio	137.06x	2.47x
P/FCF Ratio	75.37x	N/A
EV/FCF	82.17x	-17.00x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	16.38x	N/A
Forward P/S (NTM)	10.95x	N/A
Revenue & Growth
Revenue (TTM)	$238M	$0
Revenue Growth (YoY)	92.9%	N/A
Forward Rev Growth	34.7%	346.9%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	56.4%	0.0%
EBITDA Margin (TTM)	56.5%	0.0%
Net Margin (TTM)	82.4%	0.0%
FCF Margin (TTM)	7.6%	N/A
Net Income (TTM)	$196M	$-265M
FCF (TTM)	$18M	$-45M
EPS (TTM)	$3.07	-$4.34
ROE (TTM)	895.0%	-8306.0%
ROA (TTM)	57.4%	-7849.0%
ROIC (TTM)	63.2%	-8306.0%
Financial Health
Cash	$134M	$541M
Debt	$256M	$0
Net Cash/Debt	$-123M	$541M
Current Ratio (TTM)	5.61x	19.73x
Quick Ratio (TTM)	5.54x	19.70x
Debt/Equity (TTM)	24.23x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.82	-4.05
52W Performance	44.4%	-17.4%
YTD Performance	2.2%	-17.4%
% from 52W High	-37.3%	-39.6%
% from 52W Low	51.8%	27.8%
Efficiency & Yields
Asset Turnover (TTM)	0.70x	0.00x
FCF Yield (TTM)	1.3%	-3.4%
Earnings Yield (TTM)	14.4%	-20.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	100.5	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ANAB research	View DMRA research